SERPLUC

Suppression of Enzymes Required for Progression of LUng Cancer

Coordinatore	UNIVERSITY OF GLASGOW    more  Organization address address: University Avenue city: GLASGOW postcode: G12 8QQ contact info Titolo: Mr. Nome: Joe Cognome: Galloway Email: send email Telefono: +44 141 330 3884
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	100˙000 €
EC contributo	100˙000 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2013-CIG
Funding Scheme	MC-CIG
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-09-01   -   2017-08-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITY OF GLASGOW  Organization address address: University Avenue city: GLASGOW postcode: G12 8QQ contact info Titolo: Mr. Nome: Joe Cognome: Galloway Email: send email Telefono: +44 141 330 3884	UK (GLASGOW)	coordinator	100˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Suppression of enzymes required for progression of lung cancer: we propose to combine an elegant genetically engineered mouse model (GEMM) of lung cancer with an in vivo RNAi screening approach in order to functionally identify a) biomarkers of early lung cancer development and b) candidate therapeutic targets whose activities are specifically required for the transition from benign to malignant disease. We will use emerging RNA sequencing technology to identify changes in gene expression associate with early cancer progression in GEMMs of lung cancer and then select targets for RNAi suppression based on a stringent set of selection criteria aimed at zeroing in on potential drug targets, i.e.. proteins with enzymatic activity of any druggable nature that increase with tumour progression. We will then generate focused libraries of shRNAs to suppress expression of selected targets and screen their efficacy in vivo using a cunning 'drop-out' screening method. We will then subject our best candidates to rigorous validation in order to assess their suitability as therapuetic targets in the context of human lung cancer.'